Loading...
Loading...
NBIX| Name | Value |
|---|---|
| Revenues | 498.8M |
| Cost of Revenue | 11.2M |
| Gross Profit | 487.6M |
| Operating Expense | 346.4M |
| Operating I/L | 141.2M |
| Other Income/Expense | -25.6M |
| Interest Income | 15.6M |
| Pretax | 115.6M |
| Income Tax Expense | 32.5M |
| Net Income/Loss | 83.1M |
Neurocrine Biosciences, Inc. is a pharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio includes INGREZZA for tardive dyskinesia, ONGENTYS for Parkinson's disease, ORILISSA for endometriosis, and ORIAHNN for uterine fibroids. Additionally, Neurocrine Biosciences has a range of product candidates in clinical development targeting various therapeutic areas such as epilepsy, major depressive disorder, anhedonia, and schizophrenia. The company generates revenue through the sales of its commercial products and potential future sales of its product candidates upon regulatory approval.
